| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_chr6_0546400 | Intergenic-Intergenic | chr6:4713014-4718828 | chr6:4712780-4718594 | 250 nt | 0.3960 |
| hsa_CDYL_0000200 | Intron-Exon-Intron | chr6:4715458-4716115 | chr6:4715224-4715881 | 658 nt | 0.4103 |
| hsa_chr6_0546500 | Intergenic-Intergenic | chr6:4717002-4718828 | chr6:4716768-4718594 | 359 nt | 0.5014 |
| hsa_chr6_0546600 | Intergenic-Intergenic | chr6:4717568-4718828 | chr6:4717334-4718594 | 196 nt | 0.5153 |
| hsa_chr6_0546700 | Intergenic-Intergenic | chr6:4718761-4726758 | chr6:4718527-4726524 | 68 nt | 0.5147 |
| hsa_CDYL_0000400 | Intron-Intron | chr6:4786822-4787963 | chr6:4786588-4787729 | 1142 nt | 0.4781 |
| hsa_CDYL_0000500 | Intron-Intron | chr6:4793947-4794498 | chr6:4793713-4794264 | 552 nt | 0.4656 |
| hsa_CDYL_0000600 | Intron-Intron | chr6:4814195-4817526 | chr6:4813961-4817292 | 250 nt | 0.3840 |
| hsa_chr6_0550300 | Intergenic-Intergenic | chr6:4817207-4817456 | chr6:4816973-4817222 | 250 nt | 0.3680 |
| hsa_CDYL_0000700 | Intron-Intron | chr6:4817389-4817787 | chr6:4817155-4817553 | 399 nt | 0.4160 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].